Latest Integrase Stories
HAIFA, Israel and NEW YORK, Sept. 16, 2014 /PRNewswire-USNewswire/ -- If you're not making regular trips to the vet for your kitty these days, you may not know that cats can get AIDS too.
In a new study, UT Dallas researchers outline how they used fluorescent molecules to “tag” DNA and monitor a process called DNA looping, a natural biological mechanism involved in rearranging genetic material in some types of cells.
Researchers presenting late breaking research on the final day of the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) have today focussed on new studies in the field of circumcision, pre-exposure prophylaxis (PrEP) and antiretroviral treatment.
LONDON, Oct. 21 /PRNewswire/ -- Shionogi-ViiV Healthcare LLC today announced the start of the Phase III clinical programme evaluating its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572).
Researchers at IRB Barcelona have discovered this with the human cytomegalovirus, the most deadly and widespread herpesvirus and the cause of serious defects in neonates.
In a double blind trial published this week in PLoS Medicine Rajesh Gandhi and colleagues detect no significant reduction in viral load after people with low-level HIV viremia had an integrase inhibitor added to their treatment regimen.
VIENNA, July 22 /PRNewswire/ -- Shionogi-ViiV Healthcare LLC today reported data from two Phase IIb studies showing that its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572), exhibited potent antiviral activity in treatment-naive HIV subjects as well as in treatment-experienced subjects resistant to raltegravir (RAL).
LONDON, July 21 /PRNewswire/ -- Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials.
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.